Hudson Bay Capital Management’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Hudson Bay Capital Management’s Portfolio OREX Stock Details OREX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-92,266	Closed	-$5.7M	–	286
2014 Q2	$5.7M	Sell	92,266 -2,470	-3%	-$144K	0.18%	95
2014 Q1	$6.16M	Sell	94,736 -5,505	-5%	-$372K	0.17%	85
2013 Q4	$5.64M	Buy	100,241 +63,000	+169%	+$3.54M	0.23%	74
2013 Q3	$2.29M	Buy	37,241 +12,241	+49%	+$829K	0.08%	112
2013 Q2	$1.46M	Buy	+25,000	New	+$1.54M	0.08%	106

Other funds holding OREX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Hudson Bay Capital Management's OREX Position: Q3 2014 in Review

Hudson Bay Capital Management sold out of Orexigen Therapeutics, Inc. (OREX) in Q3 2014, closing a stake of 92,266 shares — an estimated $5.7M sold.

Hudson Bay Capital Management first reported a position in OREX in Q2 2013 and held it in 5 quarters. The position peaked at $6.16M in Q1 2014. 128 funds tracked by Wall St. Rank hold OREX as of Q3 2014.

Hudson Bay Capital Management reported no remaining Orexigen Therapeutics, Inc. position as of Q3 2014 after selling out during the quarter.
Hudson Bay Capital Management sold 92,266 Orexigen Therapeutics, Inc. shares in Q3 2014, an estimated $5.7M.
Hudson Bay Capital Management first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 5 quarters.
Hudson Bay Capital Management's Orexigen Therapeutics, Inc. position peaked at $6.16M in Q1 2014.
128 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q3 2014.

Based on Hudson Bay Capital Management's 13F filing for Q3 2014, filed 14 Nov 2014.